FDA Clearance Tracker · K162788
ImmuLisa Enhanced B2GP1 IgA Antibody ELISA, ImmuLisa Enhanced B2GP1 IgG Antibody ELISA, ImmuLisa Enhanced B2GP1 IgM Antibody ELISA, ImmuLisa Enhanced B2GP1 IgA/IgG/IgM Antibody ELISA
Last checked: Nov 20, 2026Latest source record: Jun 19, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 19, 2017
Substantially Equivalent
Time to decision
259 days
Received Oct 3, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K162788
- Device name
- ImmuLisa Enhanced B2GP1 IgA Antibody ELISA, ImmuLisa Enhanced B2GP1 IgG Antibody ELISA, ImmuLisa Enhanced B2GP1 IgM Antibody ELISA, ImmuLisa Enhanced B2GP1 IgA/IgG/IgM Antibody ELISA
- Applicant
- Immco Diagnostics, Inc.
- Applicant location
- Clarence, NY
- Received
- Oct 3, 2016
- Decided
- Jun 19, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5660
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MSV. The earliest in FDA's data is K970551, decided Jun 24, 1997.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K162788
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Immco Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- ImmuGlo HEp-2 Elite IFA510(k)
K172745 · Decided Jun 5, 2018 · 266 days after receipt
Device type: Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control (DHN) · Laboratory Medicine & Pathology
K172078 · Decided Mar 30, 2018 · 263 days after receipt
Device type: Autoantibodies, Anti-Ribonucleic Acid Polymerase (Rnap) Iii Antibody (NYO) · Laboratory Medicine & Pathology
K163133 · Decided Aug 8, 2017 · 273 days after receipt
Device type: Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control (DBM) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.